Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats.

Esrafil Mansouri, Mohammad-Ali Assarehzadegan, Fereshteh Nejad-Dehbashi, Wesam Kooti

Open access · greenAbstract read

In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

0.5field-weighted citation impact, top 36% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

Mechanistic pathways andIranian journal of basic medical sciences · 2026
Article
Effects of N-acetylcysteine on spexin immunoreactivity in kidney tissues of rats treated with adriamycin.Iranian journal of basic medical sciences · 2024
Article
The impact of statin use before intensive care unit admission on patients with acute kidney injury after cardiac surgery.Frontiers in pharmacology · 2023
Article
P2X7R antagonist protects against renal injury in mice with adriamycin nephropathy.Experimental and therapeutic medicine · 2022
Article
Association of Prior to Intensive Care Unit Statin Use With Outcomes on Patients With Acute Kidney Injury.Frontiers in medicine · 2021
Article
Effect of meloxicam (cyclooygenase-2 inhibitor) versus vitamin D3 (cholecalciferol) as ameliorating agents of progressive doxorubicin-induced nephrotoxicity in rats.Anatomy & cell biology · 2020
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Esrafil MansouriCellular and Molecular Research Center, Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Mohammad-Ali AssarehzadeganDepartment of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Fereshteh Nejad-DehbashiCellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Wesam KootiCellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Ahvaz Jundishapur University of Medical Sciences · IRIran University of Medical Sciences · IRSabzevar University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study is to evaluate the effects of pravastatin on Adriamycin (ADR)-induced nephropathy and the mechanisms involved. Forty rats were divided into the following 4 groups: control, ADR (15 mg.kg

Indexed as

AdriamycinNephropathyNephroprotectivePravastatinRat

Identifiers

PMID30568699

PMCPMC6269566

OpenAlexW2904762497

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.